Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.

Borrmann S., Peto T., Snow RW., Gutteridge W., White NJ.

Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.

More information Original publication

DOI

10.1371/journal.pmed.0050227

Type

Journal article

Publication Date

2008-11-18T00:00:00+00:00

Volume

5

Keywords

Animals, Antimalarials, Clinical Trials, Phase III as Topic, Drug Therapy, Combination, Humans, Malaria, Falciparum, Plasmodium falciparum, Secondary Prevention, Survival Analysis, Treatment Outcome